Effect of fibreoptic bronchoscopy on pulmonary function

Andrew J Peacock, Ronald Benson-Mitchell, Richard Godfrey

Abstract
Several studies have shown that after fibreoptic bronchoscopy there may be a deterioration in lung function but it is not known whether this is due to the premedication, the topical anaesthetic, or the obstruction produced by the bronchoscope. The effects of each part of the procedure on spirometric measurements were studied in patients with lung disease and in normal non-smokers. Measurements were made after premedication (papaveretum and atropine) in seven patients and after topical anaesthesia of the bronchial tree (340 mg lignocaine) with and without the bronchoscope in the trachea in 21 patients and 10 control subjects. Premedication had no effect. In the normal subjects lignocaine produced significant falls in FEV₁, forced vital capacity (FVC), peak expiratory flow (PEF), and peak inspiratory flow (PIF), and insertion of the bronchoscope caused further falls that were also significant. In the patients, however, although anaesthesia produced significant falls in FEV₁, FVC, PEF, and PIF of similar magnitude to those found in the normal subjects, there was no further important decrease when the bronchoscope was inserted. It is concluded that the major effect of bronchoscopy on lung function is due to topical lignocaine in the airways, and in patients with lung disease (excluding asthma or a central obstructing carcinoma) the insertion of the bronchoscope causes little additional obstruction.

It is well known that respiratory function may be disturbed after fibreoptic bronchoscopy, particularly in patients with lung disease. For example, when Salisbury et al studied lung function in normal subjects and patients with chronic airflow obstruction before and after fibreoptic bronchoscopy he found that airway resistance had increased by 23%, 15 minutes after the procedure in the patients, but not in the controls. As no one has studied the changes in lung function during bronchoscopy we do not know whether the changes that occur are due to the premedication, the topical anaesthetic, or the physical presence of the bronchoscope in the airway. Nor do we know whether changes would have been found in the normal subjects in the study of Salisbury et al if measurements had been made with the bronchoscope in the airway. In an attempt to answer these questions we have performed spirometry in 21 patients with pulmonary disease and 10 normal control subjects before, during, and after bronchoscopy.

Methods
We studied 21 patients, 17 of them male, with pulmonary disease (16 with chronic airflow obstruction, mean FEV₁ = 2.18 l, and the remainder with fibrosing lung disease, mean FEV₁ = 2.25 l). They had a mean age of 59 (range 36–75) years. In all patients fibreoptic bronchoscopy was indicated as part of their clinical care. The usual indication for bronchoscopy in the patients with airflow obstruction was suspicion of carcinoma, but none of the patients was shown to have an obstructing bronchial carcinoma. The patients with fibrosing alveolitis had bronchoscopy so that transbronchial biopsy specimens could be obtained. None of the patients was critically ill, or had a history of recent exacerbation of their lung disease. Patients with a history of asthma were excluded from the study because of the possible hazards of bronchoscopy in this group. We also studied 10 control subjects (six of them male), who were normal volunteers. All were non-smokers with normal pulmonary function and no history of atopy or respiratory disease (mean age 22 (21–23) years; mean FEV₁ 3.9 l).

Each patient was studied in the following way. After premedication with intramuscular papaveretum 10 mg and atropine 0.6 mg they were placed in a comfortable semireclining position, which was the same for all subjects and kept constant during each study. A nose clip was used to prevent nasal airflow during spirometry, which was performed with a Morgan rolling seal spirometer connected to a Hewlett Packard 85B computer. This system generated inspiratory and expiratory flow-volume (F-V) loops, from which values for FEV₁, forced vital capacity (FVC), peak expiratory flow rate (PEF), and peak inspiratory flow (PIF) were obtained. At least three F-V loops were obtained at each stage and the values associated with the best FEV₁ were recorded. Continuous earlobe oximetry (Hewlett-Packard) was started to measure change in arterial saturation (SaO₂) before the instillation of lignocaine. Two bronchoscopes were used: the Olympus BF type 1T10 (6 mm tip) in 12 patients and the Olympus BF type 4B2 (4.9 mm tip) in 9 patients. The 10 control subjects were studied by the same method except that no premedication was given. Half the control subjects had bronchoscopy with the large bronchoscope and half with the
smaller instrument. A pilot study on seven patients (five of them male; mean age 52, range 36–60 years) was carried out to assess the effect of premedication (papaveretum 10 mg and atropine 0·6 mg, both given intramuscularly) on pulmonary function. The results indicated that no significant change in pulmonary function occurred after premedication, so the baseline results reported are those obtained after premedication.

Baseline values of maximal inspiratory and expiratory flow measurements were obtained before administration of the local anaesthetic. This was administered in the form of lignocaine 2% solution given in two ways (identical for all subjects): firstly, by spray to the nasopharynx (three 10 mg puffs in each nostril, two to the back of the mouth, and two to inhale) and, secondly, in the form of 2 ml aliquots administered through the bronchoscope. Two such doses were given to the vocal cords, one to the trachea, one to the main carina, and one to each of the left and right bronchi. A total of 340 mg of lignocaine was given to each subject, after which the bronchoscope was removed. Spirometry was performed five minutes after the local anaesthetic. The bronchoscope was then reinserted transnasally and advanced to a point 5 cm above the main carina. Spirometry was repeated with the bronchoscope in position. Twenty minutes after the bronchoscopy spirometry was carried out for the final time.

To distinguish between the effects of local anaesthesia on the nasopharynx and the tracheobronchial tree, a further study was carried out to look at the effect of lignocaine spray given to the nasopharynx alone. Ten control subjects were asked to perform maximal inspiratory and expiratory flow-manoeuvres before and after administration of lignocaine spray. This was given in the way described above— that is, a total of 100 mg for each subject. Because of the wide range of baseline pulmonary function in both the patients and the control subjects (baseline PEF in the patients varied from 120 to 620 l/m), the results are expressed as percentages of baseline values. The significance of measured changes were assessed by means of paired Student's t tests and results were considered significant if p was less then 0·05.

All subjects gave informed consent to the study, which was approved by the human subjects committee of Southampton General Hospital.

Results

Topical lignocaine applied to the nasopharynx alone in the 10 control subjects caused no change in any measure of pulmonary function (mean FEV₁, FVC, PEF, and PIF in both patients and normal control subjects (figs 1 and 2 and table). In patients the percentage changes in FEV₁, FVC and inspiratory and expiratory flows were similar (8.4–10·9%) ; in the control subjects the effect on FVC was smaller (table).

The insertion of the bronchoscope caused an additional fall in the same variables but this was significant only in the normal subjects, where the principal effect was on PEF and
### Spirometric variables and change from baseline in normal control subjects and patients during bronchoscopy*

<table>
<thead>
<tr>
<th>Variable</th>
<th>FEV₁</th>
<th>FVC</th>
<th>PEF</th>
<th>PIF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NORMAL SUBJECTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD) absolute values at baseline (I or 1/min)</td>
<td>3.9 (0.5)</td>
<td>4.8 (0.53)</td>
<td>575.0 (90.0)</td>
<td>495.0 (85.0)</td>
</tr>
<tr>
<td>Mean %, (SEM) fall from baseline during bronchoscopy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>After lignocaine</td>
<td>10.2 (1.2)</td>
<td>6.5 (1.9)</td>
<td>13.5 (1.5)</td>
<td>19.1 (4.6)</td>
</tr>
<tr>
<td>Bronchoscope in airway</td>
<td>13.8 (3.0)</td>
<td>8.0 (2.0)</td>
<td>13.1 (8.0)</td>
<td>12.9 (6.0)</td>
</tr>
<tr>
<td>20 min after</td>
<td>7.5 (1.9)</td>
<td>4.0 (1.1)</td>
<td>16.5 (3.1)</td>
<td>13.6 (3.3)</td>
</tr>
<tr>
<td><strong>PATIENTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD) absolute values at baseline (I or 1/min)</td>
<td>2.2 (0.7)</td>
<td>3.1 (0.83)</td>
<td>250.0 (80.0)</td>
<td>260.0 (90.0)</td>
</tr>
<tr>
<td>Mean %, (SEM) fall from baseline during bronchoscopy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>After lignocaine</td>
<td>10.8 (2.0)</td>
<td>9.1 (2.3)</td>
<td>10.9 (2.0)</td>
<td>8.4 (2.8)</td>
</tr>
<tr>
<td>Bronchoscope in airway</td>
<td>12.5 (2.0)</td>
<td>12.7 (1.5)</td>
<td>19.3 (6.0)</td>
<td>10.0 (6.0)</td>
</tr>
<tr>
<td>20 min after</td>
<td>6.0 (2.0)</td>
<td>2.0 (2.0)</td>
<td>5.0 (2.5)</td>
<td>2.0 (3.0)</td>
</tr>
</tbody>
</table>

*The changes due to lignocaine were significant in both patients and controls (p < 0.01) but the further reductions in these variables due to the insertion of the bronchoscope were significant (p < 0.05) only in the controls.

**Flow**

Forced expiratory volume in one second; FVC—forced vital capacity; PEF—peak expiratory flow; PIF—peak inspiratory flow.

**Discussion**

In this study fibreoptic bronchoscopy caused a significant fall in forced expiried volumes and inspiratory and expiratory airflow in both patients and normal subjects. These changes have been reported previously but we were able to show that they occurred mainly after administration of the lignocaine local anaesthetic. Subsequent insertion of the bronchoscope caused some additional fall in airflow but in the patients this was relatively small by comparison with the effect of the local anaesthetic.
Further evidence of the relatively minor contribution to airflow obstruction caused by the bronchoscope was provided by the finding that the changes in spirometric values were the same whether the large or the small instrument was used. Lindholm et al calculated that a bronchoscope should reduce the cross sectional area of the trachea by 10–15%, causing a twofold rise in airway resistance. In our study insertion of the bronchoscope reduced PEF and PIF (though not FEV1 and FVC) significantly in the normal subjects but not in the patients. The explanation for this is probably that the major site of airflow resistance in normal people lies in the main bronchi whereas in patients with chronic airflow obstruction it lies distal to the trachea and the major bronchi, so that the effect of the bronchoscope lying in the trachea was not detected. An important point, however, is that none of our patients had obstructing carcinomas. If such carcinomas had been present the effect of the bronchoscope on airflow might have been greater.

The flow-volume loops were very reproducible in both patients and control subjects (fig 3). The changes we found therefore seem unlikely to be due to measurement error. Peak flow rate varies with lung volume, so some of the change in these variables might have been due to a change in total lung capacity (which we did not measure). The changes in flow, however, were most dramatic in the normal subjects, who had minor changes in FVC, and change in both total lung capacity and residual volume is unlikely without change in vital capacity.

The premedication given to the patients had no effect on expired lung volumes or flow. Indeed, the atropine may have been partially protective because the insertion of the bronchoscope had a greater effect on the controls (who did not have premedication) than on the patients (who did).

Earlobe measurement of arterial oxygen saturation showed no important change after administration of lignocaine or insertion of the bronchoscope in either patients or control subjects. This does not exclude small changes in arterial oxygenation during the studies as all the patients were on the upper, flat sections of their oxygen dissociation curves. When arterial oxygen tension has been measured during fiberoptic bronchoscopy*8 significant changes have been found, but we opted for measurement of SaO2 as a less invasive procedure in what was already a demanding protocol.

Our results suggest that the major cause of increased airflow obstruction during bronchoscopy was the topical lignocaine, but the reason for this effect is not clear. This is an important finding because the cause may be preventable. The administration of lignocaine via the bronchoscope, before anaesthesia of the airway, evidently produced irritation in most of our subjects because most coughed. Thus lignocaine may be a primary irritant but, if so, the mechanism is unknown.

The bitter taste of lignocaine may be a non-specific noxious stimulus, but the fact that the application of lignocaine to the nasopharynx alone in the control subjects had no effect suggests that this was not the pathway in our subjects.

It is well known that lignocaine may induce bronchoconstriction in subjects with hyperreactive airways,10 and Weiss and Patwardhan3 suggested that this might be mediated by prostaglandin F2α. Newball et al11 however, showed that atropine pretreatment did not prevent the bronchoconstrictor response to prostaglandin F2α in contrast to its effect on lignocaine induced bronchoconstriction. Fish and Peterman10 showed that intramuscular or nebulised atropine almost totally abolished the bronchoconstrictor response to lignocaine in asthmatic subjects, suggesting that the effect of lignocaine might be mediated by the vagus nerve.

The bronchoconstrictor effects of lignocaine solution may be related to the physicochemical properties of the solution in which it is administered. The pH of 2% lignocaine is about 6-6 and that of the 4% solution even lower; a solution at room temperature (20°C) is normally used and the solution available for injection directly down the bronchoscope is made up in distilled water. Several studies have shown that distilled water is a potent bronchoconstrictor, especially in patients with bronchial hyperreactivity. It would seem prudent to use a warmed solution made up in normal saline no more than 2% in strength. If the bronchoscopy were also preceded by administration of nebulised atropine (or, presumably, ipratropium, though this needs to be confirmed), the morbidity associated with the procedure should be reduced and patients previously thought to be unfit for bronchoscopy—paradoxically those who may need it most—could be examined with a greater margin of safety.

Effect of fibreoptic bronchoscopy on pulmonary function.

A J Peacock, R Benson-Mitchell and R Godfrey

Thorax 1990 45: 38-41
doi: 10.1136/thx.45.1.38

Updated information and services can be found at:
http://thorax.bmj.com/content/45/1/38

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/